This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
PCP: Difference between revisions
>Oskykins |
>Oskykins No edit summary |
||
| Line 7: | Line 7: | ||
|}</center> | |}</center> | ||
{{Template:SubstanceBox/PCP}} | {{Template:SubstanceBox/PCP}} | ||
'''Phencyclidine''' | '''Phencyclidine''' (also known as '''PCP''', '''Angel Dust''', or '''Sernyl''') <ref>PCP Fast Facts | http://www.justice.gov/archive/ndic/pubs4/4440/</ref> is a [[dissociative]] drug. PCP was brought to market in the 1950s as an [[Pain relief|anesthetic]] pharmaceutical drug but was taken off the market in 1965 due to the high prevalence of dissociative [[hallucinogenic]] side effects. Likewise [[ketamine]] was discovered by Parke-Davis researchers as a better-tolerated derivative for use as an anesthetic pharmaceutical drug. Since this time a number of synthetic derivatives of PCP have been sold as dissociative drugs for recreational and non-medical use.<ref>From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs | https://www.ncbi.nlm.nih.gov/pubmed/24678061</ref> | ||
In chemical structure, PCP is a member of the [[arylcyclohexylamine]] class, and, in pharmacology, it is a member of the family of dissociative anesthetics. PCP works primarily as an [[NMDA receptor antagonist]], where it blocks the activity of the NMDA receptor. As an addictive drug, PCP is associated with compulsive abuse.<ref>Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and Addictive Disorders". In Sydor A, Brown RY. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. pp. 374–375. ISBN 9780071481274. </ref><ref>From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs | https://www.ncbi.nlm.nih.gov/pubmed/24678061</ref><ref>Drugs and Behavior, 4th Edition, McKim, William A., ISBN 0-13-083146-8</ref><ref>NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2receptors¾implications for models of schizophrenia | http://www.nature.com/mp/journal/v7/n8/full/4001093a.html</ref> | In chemical structure, PCP is a member of the [[arylcyclohexylamine]] class, and, in pharmacology, it is a member of the family of dissociative anesthetics. PCP works primarily as an [[NMDA receptor antagonist]], where it blocks the activity of the NMDA receptor. As an addictive drug, PCP is associated with compulsive abuse.<ref>Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and Addictive Disorders". In Sydor A, Brown RY. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. pp. 374–375. ISBN 9780071481274. </ref><ref>From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs | https://www.ncbi.nlm.nih.gov/pubmed/24678061</ref><ref>Drugs and Behavior, 4th Edition, McKim, William A., ISBN 0-13-083146-8</ref><ref>NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2receptors¾implications for models of schizophrenia | http://www.nature.com/mp/journal/v7/n8/full/4001093a.html</ref> | ||